BR112022010943A2 - Análogos de nucleosídeos substituídos como inibidores de prmt5 - Google Patents

Análogos de nucleosídeos substituídos como inibidores de prmt5

Info

Publication number
BR112022010943A2
BR112022010943A2 BR112022010943A BR112022010943A BR112022010943A2 BR 112022010943 A2 BR112022010943 A2 BR 112022010943A2 BR 112022010943 A BR112022010943 A BR 112022010943A BR 112022010943 A BR112022010943 A BR 112022010943A BR 112022010943 A2 BR112022010943 A2 BR 112022010943A2
Authority
BR
Brazil
Prior art keywords
substituted
prmt5
prmt5 inhibitors
nucleosid
analogs
Prior art date
Application number
BR112022010943A
Other languages
English (en)
Inventor
Sreedharan Nair Prathap
Bhausaheb Gudade Ganesh
Bhaskar Bhagwat Shankar
Maruti Yadav Amol
Prabhakar Kulkarni Chaitanya
Dattatraya Sindkhedkar Milind
P Palle Venkata
Kumar Kamboj Rajender
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of BR112022010943A2 publication Critical patent/BR112022010943A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

COMPOSTO DE ANÁLOGOS DE NUCLEOSÍDEOS SUBSTITUÍDOS COMO INIBIDORES DE PRMT5, COMPOSIÇÃO FARMACÊUTICA, USO E MÉTODO PARA TRATAMENTO. A invenção refere-se a análogos de nucleosídeos substituídos de fórmula (I), seus sais farmaceuticamente aceitáveis e composições farmacêuticas para o tratamento de doenças, distúrbios ou condições associadas à superexpressão da enzima PRMT5. A invenção também se refere a métodos de tratamento de doenças, distúrbios ou condições associadas à superexpressão da enzima PRMT5
BR112022010943A 2019-12-03 2020-12-02 Análogos de nucleosídeos substituídos como inibidores de prmt5 BR112022010943A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201921049775 2019-12-03
PCT/IB2020/061372 WO2021111322A1 (en) 2019-12-03 2020-12-02 Substituted nucleoside analogs as prmt5 inhibitors

Publications (1)

Publication Number Publication Date
BR112022010943A2 true BR112022010943A2 (pt) 2022-10-11

Family

ID=74004125

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022010943A BR112022010943A2 (pt) 2019-12-03 2020-12-02 Análogos de nucleosídeos substituídos como inibidores de prmt5

Country Status (10)

Country Link
US (1) US20230066014A1 (pt)
EP (1) EP4069698A1 (pt)
JP (1) JP2023504279A (pt)
CN (1) CN115135651A (pt)
AU (1) AU2020394887A1 (pt)
BR (1) BR112022010943A2 (pt)
CA (1) CA3163421A1 (pt)
MX (1) MX2022006735A (pt)
WO (1) WO2021111322A1 (pt)
ZA (1) ZA202205799B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3980417T3 (pl) * 2019-06-10 2024-03-18 Lupin Limited Inhibitory prmt5
CA3240963A1 (en) * 2021-12-23 2023-06-29 Steven Laplante Drug combinations for inhibiting coronavirus replication
WO2024074611A1 (en) * 2022-10-05 2024-04-11 Ryvu Therapeutics S.A. Prmt5 inhibitors

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9044432B2 (en) 2009-12-22 2015-06-02 Ohio State Innovation Foundation Compositions and methods for cancer detection and treatment
GB0922332D0 (en) 2009-12-22 2010-02-03 Isis Innovation Method of treatment and screening method
EP3406607A1 (en) 2012-12-21 2018-11-28 Epizyme, Inc. Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof
EP2935241A1 (en) 2012-12-21 2015-10-28 Epizyme, Inc. Prmt5 inhibitors and uses thereof
US9221794B2 (en) 2012-12-21 2015-12-29 Epizyme, Inc. PRMT5 inhibitors and uses thereof
PL2935222T3 (pl) 2012-12-21 2019-02-28 Epizyme Inc Inhibitory PRMT5 i ich zastosowania
JP2016505000A (ja) 2012-12-21 2016-02-18 エピザイム，インコーポレイティド Ｐｒｍｔ５阻害剤およびその使用
GB201302927D0 (en) 2013-02-20 2013-04-03 Cancer Therapeutics Crc Pty Ltd Compounds
US9856218B2 (en) 2013-03-15 2018-01-02 Ohio State Innovation Foundation Inhibitors of PRMT5 and methods of their use
EP3160958B1 (en) 2014-06-25 2021-02-24 GlaxoSmithKline Intellectual Property Development Limited Crystalline salts of (s)-6-((1-acetylpiperidin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide
WO2015200677A2 (en) 2014-06-25 2015-12-30 Epizyme, Inc. Prmt5 inhibitors and uses thereof
US20170198006A1 (en) 2014-06-25 2017-07-13 Epizyme, Inc. Prmt5 inhibitors and uses thereof
CA2953572A1 (en) 2014-08-04 2016-02-11 Epizyme, Inc. Prmt5 inhibitors and uses thereof
EP3189041B1 (en) 2014-09-03 2021-04-28 Ctxt Pty Ltd Tetrahydroisoquinoline derived prmt5-inhibitors
GB201415573D0 (en) 2014-09-03 2014-10-15 Cancer Therapeutics Crc Pty Ltd Compounds
US10005792B2 (en) 2014-09-03 2018-06-26 Ctxt Pty. Ltd. Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5-inhibitors
WO2016038550A1 (en) 2014-09-11 2016-03-17 Novartis Ag Inhibition of prmt5 to treat mtap-deficiency-related diseases
UA118315C2 (uk) 2015-02-24 2018-12-26 Пфайзер Інк. Заміщені нуклеозидні похідні, прийнятні як протиракові агенти
US20180271891A1 (en) 2015-03-11 2018-09-27 The Broad Institute Inc. Selective treatment of prmt5 dependent cancer
AR104326A1 (es) 2015-05-04 2017-07-12 Lilly Co Eli Compuestos nucleósidos 5-sustituidos
TWI791251B (zh) 2015-08-26 2023-02-01 比利時商健生藥品公司 使用作為ｐｒｍｔ５抑制劑之新穎經６-６雙環芳香環取代之核苷類似物
EP3487503A1 (en) * 2016-07-20 2019-05-29 GlaxoSmithKline Intellectual Property Development Limited Isoquinoline derivatives as perk inhibitors
WO2018065365A1 (en) 2016-10-03 2018-04-12 Janssen Pharmaceutica Nv Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
WO2018085818A1 (en) 2016-11-07 2018-05-11 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018152501A1 (en) 2017-02-20 2018-08-23 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018160824A1 (en) 2017-03-01 2018-09-07 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018167800A1 (en) 2017-03-13 2018-09-20 Impetis Biosciences Limited Fused bicyclic compounds, compositions and applications thereof
CN111712498B (zh) * 2017-12-13 2023-09-29 鲁平有限公司 作为prmt5抑制剂的取代的二环杂环化合物
AU2019317549A1 (en) 2018-08-07 2021-02-25 Msd International Gmbh PRMT5 inhibitors
CN114072407A (zh) 2019-04-02 2022-02-18 阿里戈斯治疗公司 靶向prmt5的化合物
PL3980417T3 (pl) * 2019-06-10 2024-03-18 Lupin Limited Inhibitory prmt5

Also Published As

Publication number Publication date
US20230066014A1 (en) 2023-03-02
EP4069698A1 (en) 2022-10-12
CN115135651A (zh) 2022-09-30
JP2023504279A (ja) 2023-02-02
CA3163421A1 (en) 2021-06-10
WO2021111322A1 (en) 2021-06-10
AU2020394887A1 (en) 2022-06-16
MX2022006735A (es) 2022-07-21
ZA202205799B (en) 2023-01-25

Similar Documents

Publication Publication Date Title
MX2023007192A (es) Inhibidores de prmt5.
BR112022004248A2 (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para inibir a atividade de prmt5 em uma célula, e, método para o tratamento de câncer
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
BR112021024999A2 (pt) Inibidores de prmt5
CL2020001576A1 (es) Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5.
BR112022010943A2 (pt) Análogos de nucleosídeos substituídos como inibidores de prmt5
CL2019002204A1 (es) Compuestos inhibidores del vih.
BR112022000019A2 (pt) Composto da fórmula, composição farmacêutica e método de tratamento de câncer
MX2022003984A (es) Compuestos heterociclicos antivirales.
NO20090723L (no) Kondenserte heterosykliske derivater og fremgangsmater for anvendelse
BR112021023824A8 (pt) Composto, composição farmacêutica, método para inibir dna-pk e uso do composto ou da composição farmacêutica
BR112015028501B8 (pt) Compostos derivados de bipirazol, seus sais, composição compreendendo o composto ou o sal, método de inibição in vitro de uma atividade de jak1, e processo de preparação de sal de ácido fosfórico
BR112015001419A8 (pt) composto, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo
BR112022003408A2 (pt) Triazolopirimidinas como inibidores de a2a/a2b
BR112017017275A2 (pt) composto, composição farmacêutica, método para o tratamento e uso do composto
BR112017023959A2 (pt) novos compostos de sulfonimidoilpurinona e derivados para o tratamento e profilaxia de infecção por vírus
BR112022012684A2 (pt) Compostos cíclicos e métodos de uso dos mesmos
BR112019004254A2 (pt) inibidores da dopamina-b-hidroxilase penetrantes da barreira hematoencefálica
BR112017000132A2 (pt) composto, composição farmacêutica e método de tratamento ou prevenção de uma doença responsiva à inibição da atividade de pi3k
BR112021023765A2 (pt) Composto de fórmula (1), um isômero óptico, uma forma cristalina ou um sal farmaceuticamente aceitável do mesmo, inibidor de aurora quinase, composição farmacêutica de combinação e aplicação do composto
EA202091604A1 (ru) Ингибирование ионного канала a1 с транзиторным рецепторным потенциалом
BR112021020964A2 (pt) Inibidor seletivo de quinase jak1
BR112021018335A2 (pt) Derivados de benzodiazepina como inibidores de rsv
EA202190339A1 (ru) Пиридопиримидины в качестве ингибиторов н4-гистаминовых рецепторов
BR112021025618A2 (pt) Composto, método para prevenir, tratar ou diminuir a gravidade de uma doença, composição farmacêutica e uso de um composto